Aldeyra Therapeutics Inc. is a clinical-stage biotechnology company focused on discovering and developing therapies for immune-mediated and metabolic diseases. Its proprietary reactive aldehyde species (RASP) modulator platform underpins key product candidates, including reproxalap, a topical ocular investigational drug in late-stage development for dry eye disease and allergic conjunctivitis, with a New Drug Application under review by regulatory authorities. The company also advances ADX-2191, a sterile, non-compounded intravitreal methotrexate formulation designed for rare retinal conditions such as primary vitreoretinal lymphoma and retinitis pigmentosa, which has received orphan drug and fast track designations from the FDA and EMA. Additional RASP modulators like ADX-629, ADX-248, and ADX-246 target systemic immune-mediated diseases, metabolic inflammation, dermatologic conditions, liver disease, and neuroinflammatory disorders in ophthalmology, dermatology, and central nervous system areas. Headquartered in Lexington, Massachusetts, Aldeyra Therapeutics Inc. emphasizes modulating protein systems to address multiple biological pathways while minimizing toxicity, positioning it within the biotechnology sector dedicated to innovative treatments for underserved inflammatory and retinal diseases.